01 A conversation with Evercore on the market outlook
02 Will there be an alternative path to public?
03 What’s ahead for tech and life sciences IPOs?
04 The Download Quiz: Venture Capital Trends /
01A CONVERSATION WITH...more
01 Do I need to make money to go public?02 A new M&A playbook in the age of AI03 Cyber enforcement forecast post-SolarWinds decision04 Cyber diligence for IPOs with Kroll’s CISO05 The Download Quiz: Venture capital trends...more
The Securities and Exchange Commission (the “SEC”) has finalized its long-awaited rules regarding special purpose acquisition companies (“SPAC”). So, what are the key aspects of these rules that SPAC market participants...more
This report series examines quarterly trends in life sciences venture investment. Key findings for Q4 2022 include:
• Deal value reached $7.1 billion in Q4 across 392 deals, bringing the 2022 annual total to $38.0 billion...more
This report series examines quarterly trends in life sciences venture investment. Key findings for Q2 2022 include:
• The industry generated $8.8 billion in deal value across 362 deals in Q2, a material decline from Q1, as...more
This edition of Orrick’s life sciences publication series reviews the key drivers of venture investment in the life sciences industry, which is proceeding at a record pace thus far in 2021. Key findings include:
Investment...more
In this edition of Orrick’s series of life sciences publications, we offer a market update drawing on a variety of PitchBook datasets depicting macro trends in financing across the market, as well as a spotlight on any trends...more
Are direct listings a viable potential alternative for all companies seeking to go public? The answer may likely be no, especially for early stage life sciences companies that are not household names. ...more
5/18/2020
/ Broker-Dealer ,
Capital Markets ,
Capital Raising ,
Direct Listing ,
Initial Public Offering (IPO) ,
Investment ,
Investment Adviser ,
Life Sciences ,
Listing Standards ,
Nasdaq ,
NYSE ,
Publicly-Traded Companies